Your browser doesn't support javascript.
loading
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.
Jabbour, Elias; Richard-Carpentier, Guillaume; Sasaki, Yuya; Konopleva, Marina; Patel, Keyur; Roberts, Kathryn; Gu, Zhaohui; Wang, Feng; Huang, Xuelin; Sasaki, Koji; Short, Nicholas J; Jain, Nitin; Ravandi, Farhad; Daver, Naval G; Kadia, Tapan M; Alvarado, Yesid; DiNardo, Courtney D; Issa, Ghayas C; Pemmaraju, Naveen; Garcia-Manero, Guillermo; Verstovsek, Srdan; Wang, Sa; Khoury, Joseph D; Jorgensen, Jeffrey; Champlin, Richard; Khouri, Issa; Kebriaei, Partow; Schroeder, Heather; Khouri, Maria; Mullighan, Charles G; Takahashi, Koichi; O'Brien, Susan M; Kantarjian, Hagop.
Afiliación
  • Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: ejabbour@mdanderson.org.
  • Richard-Carpentier G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sasaki Y; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Patel K; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Roberts K; Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Gu Z; Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Wang F; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Huang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Alvarado Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Verstovsek S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Khoury JD; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jorgensen J; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Champlin R; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Khouri I; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kebriaei P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Schroeder H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Khouri M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mullighan CG; Department of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • O'Brien SM; Division of Hematology/Oncology, Department of Medicine, UCI Health, Orange, CA, USA.
  • Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lancet Haematol ; 7(7): e523-e533, 2020 Jul.
Article en En | MEDLINE | ID: mdl-32589978
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Leucemia-Linfoma Linfoblástico de Células Precursoras / Anticuerpos Monoclonales Humanizados Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Haematol Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Leucemia-Linfoma Linfoblástico de Células Precursoras / Anticuerpos Monoclonales Humanizados Tipo de estudio: Clinical_trials Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Haematol Año: 2020 Tipo del documento: Article